» Articles » PMID: 31397188

Changes in Serum Adipokines Profile and Insulin Resistance in Patients with Rheumatoid Arthritis Treated with Anti-TNF-

Overview
Publisher Informa Healthcare
Date 2019 Aug 10
PMID 31397188
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by an altered glucose and lipid metabolism. Tumor necrosis factor alpha (TNF-) is involved in the pathogenesis of both RA and metabolic syndrome. This study evaluated the effects of anti-TNF- agents (adalimumab, etanercept, infliximab) on lipid and glucose metabolism in patients with RA. A total of 33 RA, biological therapy- patients were recruited. Changes in Disease Activity, Body Mass Index, resistin, leptin and adiponectin serum levels, lipid profile, atherogenic index, insulin sensitivity index, and insulin resistance index were evaluated at baseline and after anti-TNF- treatments. Anti-TNF- treatment was effective in reducing disease activity. An inverse relationship between disease activity and adiponectin levels was found, whereas leptin and resistin levels directly correlated with disease activity. TNF- therapy significantly reduced leptin, resistin, and increased adiponectin. TNF- inhibition resulted in a reduction of atherogenic index and insulin resistance index while increased insulin sensitivity index. Anti-TNF- agents could have a crucial role in modifying the impact of lipid profile and glucose levels dysregulation in RA patients. TNF- inhibition may be a potential strategy for the prevention of metabolic syndrome and could play a role in the reduction of cardiovascular risk in RA.

Citing Articles

Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?.

Novella-Navarro M, Van Den Rym A, Lopez-Pedrera C, Martinez-Feito A, Nieto-Carvalhal B, Reche K Nutrients. 2025; 17(5).

PMID: 40077690 PMC: 11901994. DOI: 10.3390/nu17050820.


Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis.

Corrado A, Guadagni I, Picarelli G, Variola A Immun Inflamm Dis. 2025; 13(1):e70080.

PMID: 39760506 PMC: 11702394. DOI: 10.1002/iid3.70080.


Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis.

Grygiel-Gorniak B, Skoczek W J Clin Med. 2023; 12(18).

PMID: 37762754 PMC: 10532042. DOI: 10.3390/jcm12185814.


Beyond mechanical loading: The metabolic contribution of obesity in osteoarthritis unveils novel therapeutic targets.

Sobieh B, El-Mesallamy H, Kassem D Heliyon. 2023; 9(5):e15700.

PMID: 37180899 PMC: 10172930. DOI: 10.1016/j.heliyon.2023.e15700.


Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications.

Rani R, Raina N, Sharma A, Kumar P, Tulli H, Gupta M Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(10):2287-2310.

PMID: 37166463 DOI: 10.1007/s00210-023-02514-5.